Shares of Biogen Inc. BIIB shed 3.41% to $150.03 Friday, on what proved to be an all-around mixed trading session for the ...

This summary covers key developments in health news, including Mitsubishi Pharma's bidding war, legal actions involving J&J ...

In a rare move, the U.S. agency behind Medicare is warning Medicare Advantage providers they can’t have blanket policies that ...

Shelby Kinsey lives with a rare, fast-progressing form of ALS — but she has to spend her precious time fighting for insurance ...

Integrated Wealth Concepts LLC reduced its position in Biogen Inc. (NASDAQ:BIIB – Free Report) by 61.3% during the third ...

This health news summary discusses Lonza's exit from capsules and health ingredients, Medicare coverage mandates for Biogen's ...

The Centers for Medicare & Medicaid Services has directed private insurers providing Medicare Advantage plans to cover Biogen ...

CMS has reportedly directed Medicare Advantage plan providers to cover Biogen's drug Qalsody for ALS following reports it was ...

Beghou Consulting announced that Yair Markovits, Vishal Singal and Nicole Ventrone, have joined the company as partners. Accent Therapeutics promoted Serena Silver, PhD to chief scientific officer, ...

A stem cell transplant added to Rituxan did not improve survival for MRD-negative MCL patients in their first remission ...

The drug discovery specialist is laying off staff in a pivot that could take it private. Elsewhere, AbbVie reported a second Parkinson’s study success and Biogen hired a new Wall Street whisperer.

Biogen (NASDAQ:BIIB – Get Free Report) was downgraded by equities research analysts at Jefferies Financial Group from a “buy” ...